Introduction
Up-regulation of caveolin 1 gene expression has been demonstrated in a number of drug-resistant carcinoma cell lines [1, 2] . Caveolins, a family of membrane protein, are the main structural protein component of caveolae [3, 4] . Caveolins have been suggested to act as scaffolding proteins in order to concentrate and regulate the activity of several signaling molecules [3] [4] [5] [6] . Three different genes encode for caveolins. Caveolin 1 and 2 gene products are mainly expressed in adipocytes, endothelial and epithelial cells, as well as in fibroblasts [3] . Caveolin 3 is present exclusively in muscle cells.
Caveolin 1 has been identified as one of 26 candidate tumor suppressor genes that are down-regulated in breast cancer [7] . This observation is supported by the demonstration of caveolin 1 down-regulation in several breast and lung carcinoma cell lines [8, 9] . Moreover, caveolin 1 expression levels are dependent upon the level of activity of p53. Caveolin 1 gene expression is shut down in p53-null cells, while it is up-regulated in response to the activation of p53 [9, 10] .
A somewhat opposite view of the role of caveolin in cancer is suggested from the observation of high levels of caveolin 1 in metastatic tissues from human prostate and breast cancers [11] [12] [13] [14] . Caveolin 1 expression is also associated with androgen insensitivity of prostate cancer cells, although the mechanism of action of caveolin in this situation is still unclear [11] [12] [13] 15, 16] .
Recently, it was reported in two studies that caveolin 1 levels were dramatically up-regulated in several multidrug-resistant (MDR) cell lines compared to their drug-sensitive counterparts [1, 2] . In addition, P-glycoprotein (P-gp) was found to be enriched in caveolin-rich membrane domains after fractionation on a sucrose density gradient [1, 17] . This caveolin 1 induction was also reported in drug-resistant cell lines expressing low levels of P-gp, suggesting that caveolin 1 increase was not necessarily correlated with P-gp expression [2] .
In this study, we have investigated the effect of various cytotoxic drugs on caveolin 1 and 2 expression in drug-sensitive lung carcinoma cell lines. We now report that up-regulation of caveolin content is an early cellular response to an exposure to a cytotoxic stress.
Material and methods

Materials
Anti-caveolin 1 mouse IgG, anti-caveolin 1 rabbit IgG and anti-caveolin-2 mouse IgG were from Transduction Laboratories (Lexington, KY). Paclitaxel, doxorubicin and etoposide were purchased from Sigma (Oakville, Ontario, Canada).
Cell culture
Cell lines used in this report were obtained from the ATCC (Manassas, VA) and cultured as suggested by the supplier.
Immunoblotting
Cultured cells were collected using trypsin-EDTA, counted and pelleted by centrifugation. The pellet was then resuspended in Laemmli sample buffer, boiled for 5 min and analyzed by SDS-PAGE using caveolin 1 or 2 antibodies for Western blotting. Volumes of samples loaded on gel were corrected for the number of cells. Quantification of bands by densitometry was made using Scion Image software (Fredericks, MD).
RNA isolation and Northern analysis
RNA was isolated from cultured cells using TRIzol reagent (Life Technologies, Burlington, Ontario, Canada) following the supplier's protocol. Total RNA (5 mg) was separated on a formaldehyde-agarose gel and then transferred to a nylon membrane. A full-length caveolin 1 cDNA was labeled using the BrightStar Psoralen-Biotin kit and the detection was performed using the BrightStar Biodetect kit, both from Ambion (Austin, TX). The membrane was exposed to Kodak BioMax LS film at room temperature for 1-4 h.
Cell cycle analysis
Cells were collected, counted and pelleted by centrifugation. Cells were then washed twice with phosphatebuffered saline without Ca 2 + and Mg 2 + , and fixed in 70% ethanol at -201C for 24 h. Cells were stained in a propidium iodide solution (200 U of DNase-free RNase and 50 mg/ml of propidium iodide in water) for 30 min at room temperature and then put at 41C for at least 48 h before flow cytometric analysis. Analysis was performed on a Coulter Elite flow cytometer (Becton Dickinson, Fullerton, CA). Ten thousand events were recorded for each sample.
Results and discussion
Exposure to cytotoxic drugs is sufficient to increase caveolin 1 and 2 protein levels in various lung carcinoma cell lines. In this study, A549 and Calu-6 cells (from lung adenocarcinomas) and NIH H69 cells (from a small cell lung cancer) were used. We had previously demonstrated that these cell lines had low levels of caveolin 1 expression compared to normal lung epithelial and alveolar cells [8] . As illustrated in Figure 1 (A), exposure for 4 days to increasing amounts of doxorubicin caused a dose-dependent decrease in cellular proliferation. Simultaneously, caveolin 1 and 2 levels were markedly upregulated. Cytotoxic drugs having other mechanisms of action (VP-16 and taxol) gave similar results, as illustrated in Figure 1 (B). A549 cells exposure for 4 days to increasing concentrations of paclitaxel (taxol) or etoposide (VP-16) was accompanied with caveolin 1 and 2 upregulation of protein levels. A similar trend was observed with Calu-6 and NIH H69 cell lines (not shown). However, cells not expressing endogenous caveolins such as U937 cells (a monocyte-derived cell line) had no detectable caveolin 1 or 2 after doxorubicin treatment ( Fig. 1C ), suggesting that the cell origin is a factor in the regulation of caveolin levels. Recently, it was reported that taxol at low doses (10 nM) could increase caveolin 1 levels in A549 cells [2] . This effect was observed after 2 days of treatment. Here we show that this effect is not specific to taxol since other types of cytotoxic drugs can similarly up-regulate caveolin 1 expression. Caveolin 2 is not believed to be down-regulated in these cancer cell lines [8] . However, cytotoxic drugs had similar effects on caveolin 2 compared to caveolin 1. This effect of cytotoxic drugs on caveolin 1 and 2 expression became apparent after 24 h of treatment (not shown). Caveolin 1 mRNA is also up-regulated by cytotoxic drugs. As illustrated in Figure 1 (D), A549 cells treated with doxorubicin (50 nM) for 48 h exhibit a 3.7-fold increase in caveolin 1 mRNA levels, suggesting a regulation of caveolin cellular content at least in part at the transcription level.
We were then interested to see if these caveolin 1 and 2 levels returned to baseline after drug removal. A549 cells were cultured in the presence of a growth-inhibitory (cytostatic) dose of doxorubicin (50 nM) for 4 days and then put back in normal culture conditions. After 4 days of culture, total cell number was unchanged compared to day 0 ( Fig. 2A ). Cell counts remained unchanged for at least 3 days after drug removal. After the 4-day interval of drug exposure, caveolin 1 and 2 cell contents were increased by 10-and 15-fold, respectively, compared to those of day 0 ( Fig. 2B and C). Three days after drug removal, a slight increase in caveolin 1 levels was observed while caveolin 2 levels doubled as illustrated in Figure 2 (B and C). We let cells culture for 6 more days until cell proliferation was readily observable. By microscopic observation, we noted that only a small proportion (less than 5%) of adhering cells resumed their proliferative activity. Even then, caveolin 1 and 2 levels were still clearly elevated compared to those observed at day 0 (7 and 17 times of those of day 0, respectively). We observed such a pattern with Calu-6 cells and with VP-16 in A549 cells (not shown). We are now working to determine which cell population between proliferating and non-proliferating ones are responsible for these lasting elevated caveolin 1 and 2 levels. These results suggested that elevated caveolin content in drugresistant cells could be induced from the start of the selection, thus well before objective drug-resistance can be measured.
Caveolin 1 protein content is regulated throughout the cell cycle as has been demonstrated by others [9, 18] . Since cytotoxic drugs have major effects on the cell cycle, we were interested to correlate this parameter with the caveolin expression up-regulation we observed. In synchronized A549 lung adenocarcinoma cells as well as in NIH-3T3 fibroblasts, re-entry of cells in the S phase is accompanied by an increase of caveolin 1 and 2 levels (Fig. 3) . In fact, this increase probably happens in the late G 1 phase. Caveolin expression is relatively stable thereafter, even after 36 h when cell population distribution in the different cycle phases was similar to normally proliferating cells. Caveolin expression is therefore probably low during the G 0 and G 1 phases. These results seem in contradiction with the observation made by others that caveolin 1 expression is lower in proliferating cells in culture compared to confluent cells [19] . The amplitude of changes in caveolin protein content throughout the cell cycle we have recorded are seemingly less than those observed by Galbiati et al. between proliferating and confluent 3T3 fibroblasts, probably reflecting two different mechanisms of caveolin 1 expression control. Although it is clear that caveolin levels are controlled during the cell cycle, we do not know if the number of caveolae at the cell surface follows this trend.
A549 cells treated for 2 days with cytostatic doses of taxol, doxorubicin or VP-16 all show a blockade in the G 2 / M phase of the cell cycle ( Fig. 4) . A blockade in the late G 1 phase is also observed after treatment with doxorubicin or VP-16. DNA synthesis was clearly abrogated in doxorubicin-and VP-16-treated cells. In the case of taxol, cells undergoing apoptosis were detected by their DNA content < 2n. Caveolin 1 (Fig. 4B and C) and 2 (not shown) protein levels were clearly up-regulated in the presence of the various cytotoxic drugs used. In all cases, the proportion of cells in the G 2 phase was higher than in untreated cells, i.e. in cell cycle phase associated with higher caveolin 1 levels. However, since lower caveolin 1 and 2 levels are detected in normally cycling and synchronized cells after 1 day of serum addition compared to cells treated with cytotoxic drugs, the mechanisms of caveolin up-regulation observed in the presence of cytotoxic drugs remains unclear.
Cytotoxic drugs are well-known activators of p53, which in turn is known to up-regulate caveolin 1 expression when activated. In p53-null keratinocytes, caveolin 1 levels were shown to be strongly down-regulated [9] , while p53 activation was shown to increase the expression of a number of genes including caveolin 1 [10] . Although, activation of p53 by cytotoxic drugs could explain the upregulation of caveolin 1 and 2 levels in cells having a wildtype p53 gene such as the A549 cell line, in cell lines such as Calu-6 [19] and NCI-H69 [20] , both having mutated p53 genes, other mechanisms have to be considered.
The state of activation of the ras-mitogen-activated protein kinase (MAPK) signaling pathways is welldocumented for its control of caveolin 1 levels [21] [22] [23] . Activation of the p42/44 MAPK pathway has been shown to down-regulate caveolin 1 gene expression [21, 22] . On the other hand, activation of the p38 MAPK pathway during two differentiation processes, i.e. conversion of 3T3-L1 formation in adipocytes [24] and myotube formation in C2C12 cells [25] , has been associated with caveolin 1 and 3 induction of gene expression, respectively. Interestingly, activation of the p38 signaling pathway has been reported in cells treated with various cytotoxic drugs [26, 27] . Finally, activation by many chemotherapeutic drugs of the c-jun N-terminal protein kinase has been reported [28] but, in this case, it is not known if this MAPK family member is implicated in the regulation of caveolin expression. We are now investigating if these signaling pathways are implicated or not in this caveolin 1 and 2 induction by cytotoxic drugs in lung cancer cells.
In summary, cell exposure to cytotoxic drugs strongly increases caveolin 1 and 2 protein levels in lung cancer cell lines. This effect is regulated, at least in part, at the expression level. Although, caveolin 1 and 2 levels are modulated during the cell cycle, the magnitude of the up-regulation in caveolin levels observed after cell exposure to cytotoxic drugs is much larger, suggesting a different mechanism of regulation.
In conclusion, increases in caveolin 1 and 2 expression reported in several drug-resistant cell lines could possibly reflect exposure to cytotoxic drugs instead of being a step in the development of drug resistance. It remains to be determined if high levels of caveolin have a specific role per se in the MDR phenotype.
